Goodbye Brain Fog: Strategies to Help Get Your Thinking Back on Track
In this informative webchat, Heather Palmer, PhD, discusses symptoms, causes and solutions to cancer-related brain fog.<br /><br />This program is supported in part by the National Ovarian Cancer Coalition. L...
Author: cancerconnectasktheexpert
Added: 05/10/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 10, 2017 Category: Cancer & Oncology Source Type: podcasts
Antineoplastic Agents in Breast Cancers With Mutational Signatures
Dr Markman encourages review of recently reported possible effect of ovarian cancer antineoplastic agents in breast cancer patients with rare BRCA mutational signatures. (Source: Medscape Oncology)
Source: Medscape Oncology - April 12, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Treatment Trends for 2017: PARP Inhibitors and Immunotherapy for Gynecologic Cancers
Elizabeth Swisher, MD of University of Washington Medical Center discusses the treatment trends for ovarian cancer for 2017. She highlights the use of FDA-approved PARP inhibitors, immunotherapy, and ...
Author: SGO2017
Added: 03/31/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 31, 2017 Category: Cancer & Oncology Source Type: podcasts
ARIEL2 Trial: Hopes in Optimizing Predictor of Response
Elizabeth Swisher, MD of University of Washington Medical Center discusses her hopes in the ARIEL2 Trial in helping to optimize predictor of response for patients with not only ovarian cancer, but oth...
Author: SGO2017
Added: 03/31/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 31, 2017 Category: Cancer & Oncology Source Type: podcasts
Patient Power Partner Spotlight: SHARE Cancer Connect
Where can breast and ovarian cancer patients turn to for support? Patient Power founder Andrew Schorr visits with SHARE Cancer Connect Breast Cancer Program Director, Christine Benjamin, as she explai...
Author: patientpower
Added: 03/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 22, 2017 Category: Cancer & Oncology Source Type: podcasts
Rucaparib 'Very Active' for High-Grade Ovarian Cancer
Dr Maurie Markman reports on high response rates to rucaparib therapy for ovarian cancer and looks forward to future research efforts using this PARP inhibitor. (Source: Medscape Oncology)
Source: Medscape Oncology - March 22, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Data Suggest More Women with Ovarian Cancer Could Benefit from PARP Inhibitors
Susan C. Modesitt, MD of University of Virginia Health System discusses the use of PARP inhibitors and their benefits towards treating women with ovarian cancer. This was recorded at the 2017 Society ...
Author: SGO2017
Added: 03/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 21, 2017 Category: Cancer & Oncology Source Type: podcasts
PARP Inhibitors Very Likely Work in Ovarian Cancer without BRCA1 or BRCA2 Mutations
Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC discusses how the use of PARP Inhibitors work for Ovarian Cancer treatment without BRCA mutations. This was recorded at the 2017 Society of G...
Author: SGO2017
Added: 03/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 21, 2017 Category: Cancer & Oncology Source Type: podcasts
BRCA Mutation May Not be Necessary using PARP Inhibitors in Ovarian Cancer
Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC discusses novel agents, Olaparib and Rucaparib, that target BRCA mutations in Ovarian Cancer. He also states that even in patients who did no...
Author: SGO2017
Added: 03/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 21, 2017 Category: Cancer & Oncology Source Type: podcasts
Platinum Sensitivity an Important Predictor Using Rucaparib in Ovarian Cancer
Don Dizon, MD of Massachusetts General Hospital discusses data that argued how platinum sensitivity was an important predictor for Rucaparib response. This was recorded at the 2017 Society of Gynecolo...
Author: SGO2017
Added: 03/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 21, 2017 Category: Cancer & Oncology Source Type: podcasts
Ovarian Cancer Treatment Trends for 2017 Includes Chemotherapy, PARP Inhibitors, and Bevacizumab
Don Dizon, MD of Massachusetts General Hospital gives an overview of the treatment trends for 2017 in ovarian cancer treatment, which were discussed at the 2017 Society of Gynecologic Oncology (SGO)s...
Author: SGO2017
Added: 03/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 21, 2017 Category: Cancer & Oncology Source Type: podcasts
Olaparib and SOLO2 Trial: 52% of Patients Had a Partial Response
Don Dizon, MD of Massachusetts General Hospital gives an overview of the SOLO2 Trial and the use of olaparib in ovarian cancer. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s An...
Author: SGO2017
Added: 03/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 21, 2017 Category: Cancer & Oncology Source Type: podcasts
Olaparib and Rucaparib in the Maintenance Setting for Ovarian Cancer
Don Dizon, MD of Massachusetts General Hospital discusses the use of novel agents in ovarian cancer. He states that Olaparib and Rucaparib are not FDA approved for clinical trials but are approved for...
Author: SGO2017
Added: 03/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 21, 2017 Category: Cancer & Oncology Source Type: podcasts
